Abstract
The first biological durg used in treatment of lung cancer was bevacizumab. Bevacizumab administration, together with platinum doublet in advanced pulmonary adenocarcinoma, resulted in a slight improvement in patient survival.
Nowadays, atezolizumab may be added to this combination. The administration of bevacizumab together with tyrosine kinase inhibitors have also been studied.
Immunotherapy first demonstrated superiority over second line chemotherapy in advanced non-small cell lung cancer (NSCLC). Thereafter, immunotherapy found its application in the first line of treatment.
In selected patients on the basis of using predictive markers also in monotherapy, but in the most patients in combination with chemotherapy. Immunotherapy is also indicated for stage III NSCLC after chemoradiotherapy.
Now, immunotherapy has also found its place in small cell lung cancer. Another potential use of immunotherapy (eg as part of adjuvant post-operative treatment) has been extensively investigated.